Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A)

@inproceedings{Choi2016InhibitingSA,
  title={Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A)},
  author={Junjeong Choi and Ji-Hyun Lee and Ilkyoo Koh and Jin-Kyoung Shim and Junseong Park and Jeong Yong Jeon and Mijin Yun and Se Hoon Kim and Jong In Yook and Eui hyun Kim and Jong Hee Chang and Sun H. Kim and Yong Min Huh and Su - Jae Lee and Michael N. Pollak and Pilnam Kim and Seok-Gu Kang and Jae-Ho Cheong},
  booktitle={Oncotarget},
  year={2016}
}
Studies have investigated biguanide-derived agents for the treatment of cancers and have reported their effects against tumorspheres (TSs). The purpose of this study was determining the effects of HL156A, a newly designed biguanide with improved pharmacokinetics, on glioblastoma TSs (GMB TSs) and assess the feasibility of this drug as a new line of therapy against glioblastoma, alone or combined with a conventional therapeutic agent, temozolomide(TMZ). The effects of HL156A, alone and combined… CONTINUE READING